Alexza Pharmaceuticals, Inc. Sets Price for Initial Public Offering
March 08 2006 - 10:57AM
PR Newswire (US)
PALO ALTO, Calif., March 8 /PRNewswire-FirstCall/ -- Alexza
Pharmaceuticals, Inc. (NASDAQ:ALXA) announced today the initial
public offering of 5,500,000 shares of common stock at a price of
$8 per share. Alexza Pharmaceuticals' common stock is expected to
begin trading on the NASDAQ National Market under the trading
symbol ALXA on Wednesday, March 8, 2006. All shares are being
offered by Alexza Pharmaceuticals. The underwriters of the offering
are Piper Jaffray & Co. and Pacific Growth Equities, LLC,
acting as joint book running managers, and RBC Capital Markets and
JMP Securities, acting as co-managers. Alexza Pharmaceuticals has
granted the underwriters a 30-day option to purchase up to an
additional 825,000 shares to cover over-allotments, if any. A
registration statement relating to these securities was declared
effective by the Securities and Exchange Commission on March 7,
2006. This offering is being made by means of written prospectus.
Copies of the final prospectus relating to the offering, when
available, may be obtained from the prospectus department of either
Piper Jaffray & Co. (800 Nicollet Mall, Suite 800, Attention:
Equity Capital Markets, Minneapolis, MN 55402, by phone at
612.303.6220 or by fax at 612.303.1070), Pacific Growth Equities,
LLC (c/o Prospectus Department, One Bush Street, Suite 1700, San
Francisco, CA 94104, by phone at 415.274.6819 or by fax at
415.274.6887), RBC Capital Markets (One Liberty Plaza, New York, NY
10006, by phone at 212.858.7000 or by fax at 212.428.6200) or JMP
Securities (600 Montgomery Street, Suite 1100, San Francisco, CA
94111, by phone at 415.835.8900 or by fax at 415.835.8910). This
press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor will there be any sale of
these securities in any state or jurisdiction in which such an
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction. About Alexza Pharmaceuticals Alexza Pharmaceuticals
is an emerging pharmaceutical company focused on the development
and commercialization of novel, proprietary products for the
treatment of acute and intermittent conditions. DATASOURCE: Alexza
Pharmaceuticals, Inc. CONTACT: Thomas B. King, President & CEO
of Alexza Pharmaceuticals, Inc., +1-650-687-3900, or Web site:
http://www.alexza.com/
Copyright